Article Per Year (5 Year)
p-Index From 2021 - 2026
0.983
P-Index
This Author published in this journals
All Journal Media Farmasi : Jurnal Ilmu Farmasi (Journal Of Pharmaceutical Science) Jurnal Kedokteran dan Kesehatan : Publikasi Ilmiah Fakultas Kedokteran Universitas Sriwijaya Indonesian Journal of Cancer World Nutrition Journal Narra J Indonesian Journal of Cancer Pharmaceutical Sciences and Research (PSR) Jurnal Penyakit Dalam Indonesia
Noorwati Sutandyo
Jurusan Farmasi Klinik, Fakultas Farmasi, Universitas Indonesia, Depok, Indonesia
Biochemistry, Genetics & Molecular Biology Chemistry Health Professions Immunology & microbiology Materials Science & Nanotechnology Medicine & Pharmacology Neuroscience Public Health

Published : 17 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 17 Documents
Search

 1   2 
Validity and Reliability Test of European Organization for Research and Treatment of Cancer Quality of Life QuestionnaireBreast 23 in Breast Cancer Patient on Treatment Adli, Mizanul; Shatri, Hamzah; Sutandyo, Noorwati; Suwarto, Suhendro
Jurnal Penyakit Dalam Indonesia Vol. 7, No. 4
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Introduction. Improved survival of breast cancer patients are not necessarily followed by improvement of quality of life. According to the European Organization for Research and Treatment of Cancer (EORTC), cancer patients’ quality of life are very important to be evaluated. In Indonesia, breast cancer patients cannot be assessed their quality of life accurately because there is no valid and reliable questionnaire. This study aims to prove that the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Breast 23 (EORTC QLQ-BR23) is a valid and reliable measuring instrument to be used in Indonesia. Methods. This study was a cross-sectional study. The EORTC QLQ-BR23 questionnaire was first translated into Indonesian language before being tested on 10 respondents. The translation results were then used in 100 breast cancer patients. Test-retest was assessed with intraclass correlation coefficient (ICC), while the internal consistency was assessed by Cronbach’s alpha. Construct validity was assessed by multi-trait scaling analysis and the criteria validity assessed by identifying the correlation between domains of European Organization for Research and Treatment of Cancer Quality of Life QuestionnaireCancer 30 (EORTC QLQC30) and EORTC QLQ-BR23 with Short Form 36 (SF36). Results. From September to October 2015, a total of 100 breast cancer patients on treatment were enrolled in this study. ICC value (1 hour interval) of all EORTC QLQ-BR23 domains were very good (ICC> 0.8). ICC values (30 day interval) decrease in all EORTC QLQ-BR23 domains. Almost all of the EORTC QLQ-BR23 domains have a cronbach’s alpha value > 0.7 except for the arm symptom domain (Cronbach’s alpha: 0.643). Multi-trait scaling analysis showed a fairly high correlation between the score of the questions with a score of his own domain, while the relationship of the questions to different domains always have a lower correlation than the domain itself. In criteria validity test, obtained 19 correlation with r > 0.3 between domains of EORTC QLQ-C30 and EORTC QLQ-BR23 with SF36. Conclusion. EORTC QLQ-BR23 is a valid and reliable instrument for assessing quality of life of breast cancer patients in Indonesia
Comparison of Chemotherapy Regiments between CisplatinEtoposide and Cisplatin-Docetaxel on 2-Year and ProgressionFree Survival in Late-Stage Non-Small Cell Lung Cancer Patients Harahap, Salman Paris; Sutandyo, Noorwati; Rumende, Cleopas Martin; Shatri, Hamzah
Jurnal Penyakit Dalam Indonesia Vol. 3, No. 2
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Introduction. Chemotherapy is one of therapy choices for the advanced Non-Small Cell Lung Cancer (NSCLC). The success in therapy is measured with the 1-year survival, 2-year survival and the Progression Free Survival (PFS). The success is influenced by many factors: resistant to the citostatic, dosage, administer intensity, chemotherapy regiment, type histology, stage, performance status, comorbidity and social economic. In Indonesia, funding and chemotherapy regiment become the challenge for the success of therapy. Methods. The study used the Retrospective Cohort study with survival analysis. The Patients included in this study were the advanced NSC Lung Cancer (At least Stadium IIIa) who came to RSKD and RSCM during Jan 2006 – December 2010 for their first chemotherapy until finished the cycle (6 times) and had monitored for 2 years. Data was analyzed using cox regression analysis SPSS 16.0, and featured on the Kaplan Meier Curve. Results. Fifty five patients used EC and the other 55 patients used DC. There’s difference on survival where 1 year survival EC is 30,9% and DC is 47,3%, with p 0.030. Two year survival CE is 0% and for DC is 5.5%, with p 0.003. Also with the Median time survival between EC for 27 weeks and DC for 38 weeks with p < 0.016. Compared to DC, EC chemotherapy can increase the death risk by HR 1,684 (CI 95% 1,010-2,810), twenty four weeks PFS with EC is 54.5%, DC is 32.7% with p= 0.022. Conclusions. The survival with cisplatin-docexatel is better compared to cisplatin-etoposide, this applies to PFS as well.
Peran Pemeriksaan Penanda Tumor Cairan Pleura dalam Diagnosis Efusi Pleura Maligna Akibat Kanker Paru Primer Rumende, Cleopas M; Sutandyo, Noorwati; Hanafi, Arif R; Rumende, Samuel K; Susanto, Erwin C; Sitorus, Truely P
Jurnal Penyakit Dalam Indonesia Vol. 11, No. 3
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Introduction. Pleural effusion is a frequently acquired lung disorder and based on the type of cause it is divided into malignant and non-malignant pleural effusion. Cytological examination of pleural fluid to differentiate between malignant and non-malignant pleural effusion shows varying sensitivity. Research regarding the benefits of CEA and Cyfra 21-1 pleural fluid examination to detect malignant pleural effusion due to primary lung cancer in Indonesia is still very limited. The aims of this study is to determine the sensitivity and specificity of CEA and Cyfra 21-1 pleural fluid in diagnosing malignant pleural effusion due to primary lung camcer. Methods. A cross-sectional diagnostic study was conducted on patients with exudative pleural effusion at Dr. Cipto Mangunkusumo National Hospital (RSCM) and Darmais Cancer Hospital between September 2015 and May 2016. Patients underwent examinations for carcinoembryonic antigen (CEA) and cytokeratin 19 fragment (Cyfra 21-1) in their pleural fluid. The ROC curves were generated to determine the optimal cut-off values for CEA and Cyfra 21-1 concentrations in pleural effusion, considering the area under the curve (AUC) obtained. Chi-square tests were performed to assess sensitivity and specificity, as well as to calculate positive predictive value, negative predictive value, and accuracy for each cut-off value for both CEA and Cyfra 21-1. Results. A total of 122 patients with exudative pleural effusion, positive cytology results were obtained in 80 patients. By using the CEA cut-off value of 4.23 ng/ml, the sensitivity, specificity, positive predictive value, negative predictive value and accuracy were 87.50%, 80.95%, 89.74%, 77.27% and 85.25% with an AUC value of 0.878 (0.814 - 0.942). By using the Cyfra 21-1 cut-off value of 26.9 ng/ml, the sensitivity, specificity, positive predictive value, negative predictive value and accuracy were 78.75%, 71.43%, 84.00%, 63.82% and 76.23% with an AUC value of 0.817 (0.739 - 0.896). Conclusion. Examination of CEA and Cyfra 21-1 level in pleural fluid can be used to support the diagnose of malignant pleural effusion due to primary lung cancer.
DNA methylation profiles for breast cancer subtype classifications: A translational study from microarray to methylation-specific PCR (MSP) Panigoro, Sonar S.; Paramita, Rafika I.; Wanandi, Septelia I.; Fadilah, Fadilah; Wibisana, I GNG.; Sutandyo, Noorwati
Narra J Vol. 5 No. 1 (2025): April 2025
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v5i1.1364

Abstract

Breast cancer subtypes can be categorized based on their gene expression profiles using immunohistochemistry into Luminal A, Luminal B, human epidermal growth factor receptor 2-positive (HER2+), and triple-negative breast cancer (TNBC) subtypes. However, immunohistochemistry has certain limitations that can lead to misclassification. DNA methylation is an epigenetic modification, and changes in the promoter region can alter gene expression and the quantity of functional protein synthesized, disrupting gene function. The aim of this study was to identify DNA methylation biomarkers for subtype classification in breast cancer using microarray and methylation-specific polymerase chain reaction (MSP) methods. DNA samples were extracted, subjected to bisulfite conversion and then used for both the microarray and MSP methods. This study successfully identified differentially methylated CpGs (DMCs) as biomarker for each subtype classification of breast cancer: Luminal A (hypermethylation of ADAMTSL2 gene; cg14397888), Luminal B (hypomethylation of ADAMTSL2 gene; cg14397888), HER2+ (hypermethylation of PTPRN2 gene; cg25910261), and TNBC (hypomethylation of LCLAT1 gene; cg15652532). The DMC biomarker found for the HER2+ subtype, hypermethylation in the PTPRN2 gene (cg25910261), has the potential to be used by healthcare providers to identify HER2+ patients and provide the HER2-targeted therapy to improve the patient’s survival. In addition, our developed MSP method could produce an effective diagnostic tool for classifying the Luminal A and Luminal B subtypes, with accuracies of 75% and 76%, respectively.
Faktor Yang Mempengaruhi Penurunan Fraksi Ejeksi Ventrikel Kiri Pada Pasien Kanker Yang Mendapatkan Kemoterapi Doksorubisin Di Rumah Sakit Kanker Dharmais Maifitrianti, Maifitrianti; Sutandyo, Noorwati; Andrajati, Retnosari
Media Farmasi: Jurnal Ilmu Farmasi Vol. 12 No. 2: September 2015
Publisher : Universitas Ahmad Dahlan

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.12928/mf.v12i2.3761

Abstract

Doksorubisin masih sering digunakan dalam pengobatan kanker. Efek samping doksorubisin terhadap jantung perlu mendapatkan perhatian khusus. Penelitian ini bertujuan untuk memperoleh gambaran penurunan fraksi ejeksi ventrikel kiri dan faktor risiko yang mempengaruhinya pada pasien kanker yang mendapatkan kemoterapi doksorubisin di Rumah Sakit Kanker Dharmais (RSKD). Desain penelitian yang digunakan adalah cross sectional. Data diperoleh dari rekam medis pasien. Populasi adalah pasien kanker yang mendapatkan kemoterapi doksorubisin minimal 4 siklus periode Oktober 2011-Oktober 2013. Penilaian fungsi jantung didapatkan dari data Echocardiography jantung yaitu fraksi ejeksi ventrikel kiri sebelum kemoterapi dan setelah siklus terakhir kemoterapi. Penurunan fraksi ejeksi ventrikel kiri ≥10% pada penelitian dinilai sebagai penurunan yang bermakna. Analisis statistik menggunakan software Statistical Products Social Science (SPSS) versi 18. Sebanyak 77 pasien memenuhi kriteria inklusi dan eklusi. Sebanyak 37 pasien (48,05%)  mengalami penurunan fraksi ejeksi ventrikel kiri <10% dan sebanyak  28  pasien  (36,36%) mengalami penurunan fraksi ejeksi ventrikel kiri ≥10%. Hipertensi berpengaruh terhadap penurunan fraksi ejeksi ventrikel kiri ≥10% secara bermakna (p=0,032). Jenis kelamin laki-laki dan radiasi dada kiri menunjukkan adanya kecenderungan berhubungan dengan penurunan fraksi ejeksi ventrikel kiri ≥10% (p=0,095 dan p=0,051). Doksorubisin dapat menyebabkan penurunan fraksi ejeksi ventrikel kiri ≥10% pada lebih dari sepertiga pasien kanker di RSKD dan faktor yang paling mempengaruhinya adalah komorbiditas hipertensi. Kata Kunci: doksorubisin; faktor risiko; penurunan fraksi ejeksi ventrikel kiri 
Factor Associated with Mortality of Hospitalized Cancer Patients with COVID-19 Infection in Indonesia National Cancer Center Kurniawati, Sri Agustini; Sutandyo, Noorwati; Tadjoedin, Hilman; Pradipta, Jaka; Ismuha, Ratu Ralna; Ummah, Citra Dovina Khaira; Suryana, Kresna Dharma; Budi, Erwin
Indonesian Journal of Cancer Vol 18, No 2 (2024): June
Publisher : http://dharmais.co.id/

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v18i2.1077

Abstract

Background: Cancer patients with COVID-19 are at risk of developing severe complications and outcomes due to immunosuppressive and inflammatory states. This study aims to provide insight into risk factors associated with mortality in this population. Methods: A retrospective cohort study was conducted at Dharmais National Cancer Center, Jakarta, Indonesia, from May 2020 to July 2021. Data were collected through electronic medical records using the consecutive sampling technique. The numerical and categorical data were then tested statistically. Results: The results showed 180 cancer patients with COVID-19 were hospitalized at Dharmais National Cancer Center. Among the patients, 114 patients survived, and 66 patients deceased. Across all risk factors analyzed to mortality, patients with Diabetes Mellitus (OR 0.41;0.22-0.77, p-value 0.05) and high level of D-dimer (OR 2.00;1.06-3.79, P-value 0.05) have a higher risk in mortality. The Results showed that survived patients have lower D-dimer levels (2010 ng/L) and deceased patients have higher D-dimer levels (3264 ng/L) with P-value 0.05. Conclusion: High D-dimer levels and diabetes are risk factors significantly associated with mortality in hospitalized cancer patients with COVID-19 Infection.
VALIDITY, RELIABILITY, AND DIAGNOSTIC PERFORMANCE OF GERIATRIC-8 AS A SCREENING TOOL FOR ABNORMAL COMPREHENSIVE GERIATRIC ASSESSMENT Ridzqie Dibyantari; Nina Kemala Sari; Edy Rizal Wahyudi; Muhadi; Aulia Rizka; Arif Mansjoer; Noorwati Sutandyo
Jurnal Kedokteran dan Kesehatan : Publikasi Ilmiah Fakultas Kedokteran Universitas Sriwijaya Vol. 13 No. 2 (2026): Jurnal Kedokteran dan Kesehatan : Publikasi Ilmiah Fakultas Kedokteran Univers
Publisher : Fakultas Kedokteran Universitas Sriwijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32539/jkk.v13i2.728

Abstract

The Geriatric Patient Plenary Assessment (P3G) is useful in the management of the elderly, but it is time-consuming, so screening instruments such as the Geriatric 8 (G8) have been developed. Initially designed for cancer patients, the G8 has also been shown to be valid in non-cancer elderly patients, but there have been no studies in Indonesia. This cross-sectional study (August 2023–March 2024) at the Geriatrics Clinic of Cipto Mangunkusumo National Hospital involved 80 subjects who underwent P3G and G8. An abnormal P3G was defined as impaired in ≥1 domain (ADL <20, IADL <8, MNA <24, MoCA-INA <26, or GDS >4). The results showed strong reliability (inter-rater kappa 1; intra-rater 0.904; ICC 0.77–1; Cronbach's α 0.697). The G8 had a sensitivity of 70.27% and a specificity of 83.33%, with an AUC of 0.846 (p<0.005). These findings demonstrate good diagnostic performance in identifying elderly individuals requiring a complete P3G. It is concluded that the G8 is valid and reliable as a screening tool for elderly individuals in the general Indonesian population, with good specificity.
Co-Authors A. M. Jayusman Adli, Mizanul Anwar Jusuf Arif Mansjoer ARIF R HANAFI, ARIF R Aulia Rizka Birry Karim Budi, Erwin Cleopas M Rumende, Cleopas M Cleopas Martin Rumende Cosphiadi Irawan Diana Sunardi Dolly Dolven Kansera E. Mudjaddid A. Siswanto Deddy N.W.Achadiono Hamzah Shatri Eddy Suratman Edy Rizal Wahyudi EKA WIDYA KHORINAL, EKA WIDYA Em Yunir, Em Erlina Burhan Fadlina Chany Saputri Griskalia Christine Harahap, Agnes S. HILMAN TADJOEDIN, HILMAN Joedo Prihartono Kardinah -, Kardinah Lugyanti Sukrisman Luhuna, Muslimah Maifitrianti Maifitrianti Maifitrianti Maifitrianti, Maifitrianti Maifitrianti, Maifitrianti Mohamad Sadikin Muhadi Mun'im, Abdul NATA LUGITO, NATA Paramita, Rafika I. Patricia Amanda Philip Waruna, Philip Pradipta, Jaka Ratu Ralna Ismuha Reni Paramita Retnosari Andrajati Retnosari Andrajati Ridzqie Dibyantari Rizki Yaruntradhani Rumende, Samuel K Salman Paris Harahap, Salman Paris Sari, Nina Kemala Sariasih Arumdati Septelia I. Wanandi Setyawan, Lyana Sitorus, Truely P Sonar Panigoro Sri Agustini Kurniawati, Sri Agustini Sri Wardatun Suhendro Suwarto, Suhendro Suryana, Kresna Dharma Susanto, Erwin C Ummah, Citra Dovina Khaira Wibisana, I GNG. Yahdiana Harahap